SkinBioTherapeutics plc SkinBiotix® technology successful in stability testing

SkinBioTherapeutics involved in a c.£600k research grant NORTHLAND VIEW SkinBio announced it is the industrial partner for a c.£600k grant awarded by the Biotechnology and Biological Sciences Research Council (BBSRC) to The University of Manchester. The

The skin surface is composed of molecules derived from our skin cells, our environment and from the microorganisms living on our skin. The composition and the diversity of skin microorganisms are directly linked to parameters such

The microbiome has been generating a lot of buzz lately, and for good reason. Recent studies have shown that there’s a connection between the microbes in your digestive tract and everything from your mental health to irritable bowel syndrome. Lately, we’ve

New patent application filed for SkinBiotix® platform NORTHLAND VIEW SkinBio announced a new patent filing regarding the use of SkinBiotix®, the Company’s proprietary probiotic platform, for increasing filaggrin levels in skin. Filaggrin is a protein vital

SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announced today a new patent filing. The patent application is to cover the use of SkinBiotix® for increasing filaggrin levels in skin. Filaggrin is a protein

NIH study suggests a potentially cheap and effective treatment for a painful condition. Inflammation, itching, painful skin lesions: This is everyday life for patients with atopic dermatitis, a type of eczema that affects roughly 11 percent of adults

Human study design and manufacturing scale-up for cosmetic application NORTHLAND VIEW Human study: SkinBio provided the finalised design of its human study, which aims to test the efficacy of the cosmetic application of Skinbiotix®, the company’s

Dr Catherine O’Neill, CEO of SkinBioTherapeutics, commented: “The incorporation of our SkInBiotix(R) technology into an effective cream formulation is a major milestone in the development of products for the cosmetic market and, subject to stability testing,

Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA.  Even at this early stage

The microbiome is the genetic material of all the microbes – bacteria, fungi, protozoa and viruses – that live on and inside the human body. The microbiome has essential beneficial functions relevant to supporting life and